182
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Escitalopram in clinical practice in Greece: treatment response and tolerability in depressed patients

, , , , , , , & show all
Pages 937-945 | Published online: 13 Apr 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Daniel Souery, Raffaella Calati, Konstantinos Papageorgiou, Alzbeta Juven-Wetzler, Joël Gailledreau, David Modavi, Othman Sentissi, William Pitchot, George N. Papadimitriou, Dimitris Dikeos, Stuart Montgomery, Siegfried Kasper, Joseph Zohar, Alessandro Serretti & Julien Mendlewicz. (2015) What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram. The World Journal of Biological Psychiatry 16:7, pages 472-482.
Read now
Alain Gérard, François Liard, Anne Crochard, Sylvia Goni & Bruno Millet. (2012) Disability in patients consulting for anxiety or mood disorders in primary care: response to antidepressant treatment. Neuropsychiatric Disease and Treatment 8, pages 605-614.
Read now

Articles from other publishers (4)

Ae-Jin Goo, Eun-Kyung Won, Cheolsoon Lee, Jong-Il Lee, Hee-Yeon Jung & Yeni Kim. (2013) Long-Term Tolerability of Escitalopram in Korean Adolescents. Journal of the Korean Academy of Child and Adolescent Psychiatry 24:4, pages 207-212.
Crossref
Nicolas Despiégel, Natalya Danchenko, Clément François, Benedikte Lensberg & Michael F. Drummond. (2012) The Use and Performance of Productivity Scales to Evaluate Presenteeism in Mood Disorders. Value in Health 15:8, pages 1148-1161.
Crossref
Jian-Jun Ou, Guang-Lei Xun, Ren-Rong Wu, Le-Hua Li, Mao-Sheng Fang, Hong-Geng Zhang, Shi-Ping Xie, Jian-Guo Shi, Bo Du, Xue-Qin Yuan & Jing-Ping Zhao. (2010) Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study. Psychopharmacology 213:2-3, pages 639-646.
Crossref
Karly P. Garnock-Jones & Paul L. McCormack. (2010) Escitalopram. CNS Drugs 24:9, pages 769-796.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.